Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study

Abd-Elsalam et al., Journal of Medical Virology, doi:10.1002/jmv.27122
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 25% primary Improvement Relative Risk Ventilation 0% Hospitalization time 20% Ivermectin  Abd-Elsalam et al.  LATE TREATMENT  RCT Is late treatment with ivermectin beneficial for COVID-19? RCT 164 patients in Egypt (March - October 2020) Shorter hospitalization with ivermectin (not stat. sig., p=0.085) c19ivm.org Abd-Elsalam et al., J. Medical Virology, Jun 2021 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
RCT 164 hospitalized patients in Egypt showing lower mortality and shorter hospitalization, but without statistical significance. There were no serious adverse effects. Authors suggest the low dosage may have resulted in lower efficacy than other trials, and recommend increased dosage in future trials. Time from symptom onset is not specified. The trial was retrospectively registered and the recruitment start date in the trial registration (June 2020) differs from the paper (March 2020)1. For other concerns see2.
This is the 25th of 51 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000015.
This is the 55th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of death, 25.0% lower, RR 0.75, p = 0.70, treatment 3 of 82 (3.7%), control 4 of 82 (4.9%), NNT 82, odds ratio converted to relative risk, logistic regression, primary outcome.
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 3 of 82 (3.7%), control 3 of 82 (3.7%).
hospitalization time, 19.6% lower, relative time 0.80, p = 0.09, treatment 82, control 82.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abd-Elsalam et al., 2 Jun 2021, Randomized Controlled Trial, Egypt, peer-reviewed, 16 authors, study period March 2020 - October 2020, dosage 12mg days 1-3.
This PaperIvermectinAll
Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study
Sherief Abd‐elsalam, Rasha A Noor, Rehab Badawi, Mai Khalaf, Eslam S Esmail, Shaimaa Soliman, Mohamed S Abd El Ghafar, Mohamed Elbahnasawy, Ehab F Moustafa, Sahar M Hassany, Mohammed A Medhat, Haidi Karam‐allah Ramadan, Maii A S Eldeen, Mohamed Alboraie, Ahmed Cordie, Gamal Esmat
Journal of Medical Virology, doi:10.1002/jmv.27122
Researchers around the world are working at record speed to find the best ways to treat and prevent coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID-19 infected patients. This was a randomized open-label controlled study that included 164 patients with COVID-19. Patients were randomized into
References
Abd-Elsalam, Esmail, Khalaf, Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study, Am J Trop Med Hyg
Abd-Elsalam, Esmail, Khalaf, Tanta protocol for management of COVID-19: perspectives from a developing country
Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos, QJM
Behera, Patro, Singh, Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, J Med Virol
Caccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, doubleblind, placebo-controlled, randomized clinical trial, EClinicalMedicine
Caly, Druce, Catton, Jans, Wagstaff, The FDAapproved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Cappello, Marchetti, Parlanti, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep
Chaccour, Hammann, Ramón-García, Rabinovich, Ivermectin and COVID-19: keeping rigor in times of urgency, Am J Trop Med Hyg
Chachar, Khan, Asif, Tanveer, Khaqan et al., Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci
Elgazzar, Eltaweel, Youssef, Hany, Hafez et al., Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic
Faul, Erdfelder, Lang, Buchner, Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences, Behav Res Methods
Galan, Santos, Asato, Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathog Glob Health, doi:10.1080/20477724.2021.1890887
Gallegos, WHO Declares Public Health Emergency for Novel Coronavirus, Medscape Medical News
Gandhi, Lynch, Del Rio, Mild or moderate COVID-19, N Engl J Med
Gorial, Mashhadani, Sayaly, Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Jans, Martin, Wagstaff, Inhibitors of nuclear transport, Curr Opin Cell Biol
Khan, Khan, Debnath, Ivermectin treatment may improve the prognosis of patients with COVID-19, Arch Bronconeumol, doi:10.1016/j.arbres.2020.08.007
Lundberg, Pinkham, Baer, Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan equine encephalitis virus replication, Antiviral Res
Masoud, Elassal, Zaky, Management Protocol for COVID-19 Patients
Mccreary, Pogue, Coronavirus disease 2019 treatment: a review of early and emerging options, Open Forum Infect Dis
Mohamed, Mohamed, Mohamoud, SARS-CoV-2: the path of prevention and control
Momekov, Momekova, Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens, Biotechnol Biotechnol Equip
Podder, Chowdhury, Mohim, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study, IMC J Med Sci
Pott-Junior, Paoliello, Miguel, Use of ivermectin in the treatment of Covid-19: a pilot trial, Toxicol Rep
Prokop, Van Everdingen, Vellinga, CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19 definition and evaluation, Radiology
Rajter, Sherman, Vogel, Sacks, Rajter, Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ivermectin in COVID nineteen study, Chest
Sharun, Dhama, Patel, Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Clin Microbiol Antimicrob, doi:10.1186/s12941-020-00368-w
Struyf, Deeks, Dinnes, Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease, Cochrane Database Syst Rev
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin, Antiviral Res
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T20:33:19Z', 'timestamp': 1712608399790}, 'reference-count': 30, 'publisher': 'Wiley', 'issue': '10', 'license': [ { 'start': { 'date-parts': [[2021, 6, 7]], 'date-time': '2021-06-07T00:00:00Z', 'timestamp': 1623024000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 10]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:label /><jats:p>Researchers around the world ' 'are working at record speed to find the best ways to treat and prevent coronavirus disease ' '2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin for the treatment of ' 'hospitalized mild to moderate COVID‐19 infected patients. This was a randomized open‐label ' 'controlled study that included 164 patients with COVID‐19. Patients were randomized into two ' 'groups where Group 1 (Ivermectin group) included patients who received ivermectin 12\u2009mg ' 'once daily for 3 days with standard care and Group 2 (control group) included patients who ' 'received standard protocol of treatment alone for 14 days. The main outcomes were mortality, ' 'the length of hospital stay, and the need for mechanical ventilation. All patients were ' 'followed up for 1 month. Overall, 82 individuals were randomized to receive ivermectin plus ' 'standard of care and 82 to receive standard of care alone. Patients in the ivermectin group ' 'had a shorter length of hospital stay (8.82\u2009±\u20094.94 days) than the control group ' '(10.97\u2009±\u20095.28 days), but this was not statistically significant ' '(<jats:italic>p</jats:italic>\u2009=\u20090.085). Three patients (3.7%) in each group ' 'required mechanical ventilation (<jats:italic>p</jats:italic>\u2009=\u20091.00). The death ' 'rate was three patients in the ivermectin group (3.7%) versus four patients (4.9%) in the ' 'control group without any significant difference between the two groups ' '(<jats:italic>p</jats:italic>\u2009=\u20091.00). Although there was no statistically ' 'significant difference in any endpoints by ivermectin doses (12\u2009mg/day for 3 days); ' 'there was an observed trend to reducing hospital stay in the ivermectin‐treated ' 'group.</jats:p></jats:sec>', 'DOI': '10.1002/jmv.27122', 'type': 'journal-article', 'created': {'date-parts': [[2021, 6, 2]], 'date-time': '2021-06-02T17:42:09Z', 'timestamp': 1622655729000}, 'page': '5833-5838', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 70, 'title': 'Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized ' 'controlled study', 'prefix': '10.1002', 'volume': '93', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-4366-2218', 'authenticated-orcid': False, 'given': 'Sherief', 'family': 'Abd‐Elsalam', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Infectious diseases, Faculty ' 'of Medicine Tanta University Tanta Egypt'}]}, { 'given': 'Rasha A.', 'family': 'Noor', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Internal Medicine, Faculty of Medicine Tanta ' 'University Tanta Egypt'}]}, { 'given': 'Rehab', 'family': 'Badawi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Infectious diseases, Faculty ' 'of Medicine Tanta University Tanta Egypt'}]}, { 'given': 'Mai', 'family': 'Khalaf', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Infectious diseases, Faculty ' 'of Medicine Tanta University Tanta Egypt'}]}, { 'given': 'Eslam S.', 'family': 'Esmail', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Infectious diseases, Faculty ' 'of Medicine Tanta University Tanta Egypt'}]}, { 'given': 'Shaimaa', 'family': 'Soliman', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Public health and Community Medicine, Faculty of ' 'Medicine Menoufia University Menoufia Egypt'}]}, { 'given': 'Mohamed S.', 'family': 'Abd El Ghafar', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Anesthesia, Surgical Intensive Care, and Pain ' 'Medicine, Faculty of Medicine Tanta University Tanta Egypt'}]}, { 'ORCID': 'http://orcid.org/0000-0001-8706-4389', 'authenticated-orcid': False, 'given': 'Mohamed', 'family': 'Elbahnasawy', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Emergency Medicine and traumatology, Faculty of ' 'Medicine Tanta University Tanta Egypt'}]}, { 'given': 'Ehab F.', 'family': 'Moustafa', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Gastroenterology, Faculty of ' 'Medicine Assiut University Assiut Egypt'}]}, { 'given': 'Sahar M.', 'family': 'Hassany', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Gastroenterology, Faculty of ' 'Medicine Assiut University Assiut Egypt'}]}, { 'given': 'Mohammed A.', 'family': 'Medhat', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Gastroenterology, Faculty of ' 'Medicine Assiut University Assiut Egypt'}]}, { 'given': 'Haidi Karam‐Allah', 'family': 'Ramadan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Tropical Medicine and Gastroenterology, Faculty of ' 'Medicine Assiut University Assiut Egypt'}]}, { 'given': 'Maii A. S.', 'family': 'Eldeen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Microbiology and Immunology Tanta University ' 'Tanta Egypt'}]}, { 'given': 'Mohamed', 'family': 'Alboraie', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Internal Medicine Al‐Azhar University Cairo ' 'Egypt'}]}, { 'given': 'Ahmed', 'family': 'Cordie', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Endemic Medicine, Kasr Alainy School of Medicine ' 'Cairo University Cairo Egypt'}]}, { 'given': 'Gamal', 'family': 'Esmat', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Endemic Medicine, Kasr Alainy School of Medicine ' 'Cairo University Cairo Egypt'}]}], 'member': '311', 'published-online': {'date-parts': [[2021, 6, 7]]}, 'reference': [ { 'key': 'e_1_2_7_2_1', 'unstructured': 'GallegosA. WHO Declares Public Health Emergency for Novel Coronavirus. ' 'Medscape Medical News Available ' 'athttps://www.medscape.com/viewarticle/924596.2020.'}, {'key': 'e_1_2_7_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMcp2009249'}, { 'issue': '7', 'key': 'e_1_2_7_4_1', 'first-page': 'CD013665', 'article-title': 'Signs and symptoms to determine if a patient presenting in primary care ' 'or hospital outpatient settings has COVID‐19 disease', 'volume': '7', 'author': 'Struyf T', 'year': '2020', 'journal-title': 'Cochrane Database Syst Rev'}, {'key': 'e_1_2_7_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofaa105'}, {'key': 'e_1_2_7_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4269/ajtmh.20-0271'}, {'key': 'e_1_2_7_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-016-0001-8'}, { 'key': 'e_1_2_7_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2013.10.004'}, { 'key': 'e_1_2_7_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2013.06.002'}, {'key': 'e_1_2_7_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.4269/ajtmh.20-0873'}, { 'key': 'e_1_2_7_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104787'}, { 'key': 'e_1_2_7_12_1', 'unstructured': 'MasoudHH ElassalG ZakyS et al. Management Protocol for COVID‐19 ' 'Patients. Ministry of health and population (MOHP) Egypt. Version 1.4 ' 'May2020.http://www.mohp.gov.eg/JobsDetails.aspx?job_id=3061'}, {'key': 'e_1_2_7_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.11.191'}, { 'key': 'e_1_2_7_14_1', 'article-title': 'Efficacy and safety of ivermectin for treatment and prophylaxis of ' 'COVID‐19 pandemic', 'author': 'Elgazzar A', 'year': '2020', 'journal-title': 'Res Square'}, {'key': 'e_1_2_7_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12941-020-00368-w'}, {'key': 'e_1_2_7_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ceb.2019.01.001'}, { 'key': 'e_1_2_7_17_1', 'article-title': 'Effectiveness of Ivermectin as add‐on Therapy in COVID‐19 Management ' '(Pilot Trial) [published online ahead of print July 08, 2020]', 'author': 'Gorial FI', 'year': '2020', 'journal-title': 'MedRxiv'}, { 'key': 'e_1_2_7_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.arbres.2020.08.007'}, { 'issue': '3', 'key': 'e_1_2_7_19_1', 'first-page': '002', 'article-title': 'Outcome of ivermectin treated mild to moderate COVID‐19 cases: a ' 'single‐centre, open‐label, randomized controlled study', 'volume': '14', 'author': 'Podder CS', 'year': '2020', 'journal-title': 'IMC J Med Sci'}, { 'key': 'e_1_2_7_20_1', 'first-page': '31', 'article-title': 'Effectiveness of ivermectin in SARS‐CoV‐2/COVID‐19 patients', 'author': 'Chachar AZK', 'year': '2020', 'journal-title': 'Int J Sci'}, { 'key': 'e_1_2_7_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/13102818.2020.1775118'}, {'key': 'e_1_2_7_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3758/BF03193146'}, { 'key': 'e_1_2_7_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eclinm.2020.100720'}, { 'key': 'e_1_2_7_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chest.2020.10.009'}, { 'key': 'e_1_2_7_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.toxrep.2021.03.003'}, {'key': 'e_1_2_7_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/qjmed/hcab035'}, {'key': 'e_1_2_7_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1148/radiol.2020201473'}, { 'key': 'e_1_2_7_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/20477724.2021.1890887'}, { 'key': 'e_1_2_7_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1871530320999201117142305'}, { 'key': 'e_1_2_7_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/1871526520666200520112848'}, { 'key': 'e_1_2_7_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0247163'}], 'container-title': 'Journal of Medical Virology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27122', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jmv.27122', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27122', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 8, 25]], 'date-time': '2023-08-25T22:54:29Z', 'timestamp': 1693004069000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/jmv.27122'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 6, 7]]}, 'references-count': 30, 'journal-issue': {'issue': '10', 'published-print': {'date-parts': [[2021, 10]]}}, 'alternative-id': ['10.1002/jmv.27122'], 'URL': 'http://dx.doi.org/10.1002/jmv.27122', 'relation': {}, 'ISSN': ['0146-6615', '1096-9071'], 'subject': ['Infectious Diseases', 'Virology'], 'container-title-short': 'Journal of Medical Virology', 'published': {'date-parts': [[2021, 6, 7]]}, 'assertion': [ { 'value': '2021-05-29', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-05-31', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-06-07', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit